Jerry Bagel (J Bagel)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 6

Top Topics

Ankylosing Spondylitis

Top Venues

The Journal of dermatological treatment

Dermatology and therapy

Journal of the European Academy of Dermatology and Venereology : JEADV

This page only lists publications with an associated author ORCID identifier.

Publications

Neil J Korman, Richard Bruce Warren, Jerry Bagel, April W Armstrong, Melinda J Gooderham, Bruce E Strober, Diamant Thaҫi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, Lauren Hippeli, Renata M Kisa, Subhashis Banerjee, Andrew Blauvelt
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. The Journal of dermatological treatment 35 (1) (2024)
Andrew Blauvelt, Robert R McLean, Silky W Beaty, Adam P Sima, Robert Low, Jeffrey L Stark, Laura McClung, Jerry Bagel
Impact of Disease Burden of Patients with Psoriasis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry. Dermatology and therapy (2024)
Neil J Korman, Richard Bruce Warren, Jerry Bagel, April W Armstrong, Melinda J Gooderham, Bruce E Strober, Diamant Thaҫi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, Lauren Hippeli, Renata M Kisa, Subhashis Banerjee, Andrew Blauvelt
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. The Journal of dermatological treatment 35 (1) (2024)
Andrew Blauvelt, April W Armstrong, Richard G Langley, Kurt Gebauer, Diamant Thaҫi, Jerry Bagel, Lyn C Guenther, Carle F Paul, Bruce Randazzo, Susan Flavin, Ming-Chun Hsu, Yin You, Kristian Reich
Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. The Journal of dermatological treatment (2021)
Jerry Bagel, Andrew Blauvelt, J Nia, P Hashim, M Patekar, A de Vera, K Ahmad, B Paguet, S Xia, E Muscianisi, M Lebwohl
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). Journal of the European Academy of Dermatology and Venereology : JEADV 35 (1) (2020)
Jerry Bagel, Elise Nelson, James Zapata, Alexa Hetzel
Adjunctive Use of Calcipotriene/Betamethasone Dipropionate Foam in a Real-World Setting Curtails the Cost of Biologics Without Reducing Efficacy in Psoriasis. Dermatology and therapy 10 (6) (2020)